Diagnostic and prognostic value of biomarkers in acute myocardial infarction

Chen, Yuqi; Tao, Yifei; Zhang, Lan; Xu, Weiting; Zhou, Xiang

doi:10.1136/postgradmedj-2019-136409

Cited by 65 publications

(57 citation statements)

References 93 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further comparison of HIF-1 and VEGF levels between the routine therapy group and the study group showed that the content in the study group was higher than that in the routine therapy group, suggesting that the combination of atorvastatin and routine therapy increased the concentrations of HIF-1 and VEGF. HIF-1 is the key factor of cell regulation in hypoxia (21). HIF-1 can stimulate the release of VEGF-A when cells are anoxic.…”

Section: Discussionmentioning

confidence: 99%

Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Zhang

2020

Exp Ther Med

View full text Add to dashboard Cite

Effect of atorvastatin combined with routine therapy on the expression of hypoxia inducible factor (HIF-1) and vascular endothelial growth factor (VEGF) in rats with acute myocardial infarction (AMI) and its therapeutic effect were investigated. The rat models of acute myocardial infarction were established and divided into routine therapy, study, model, single drug and control group according to the treatment plan, with 10 cases in each group. Enzyme-linked immunosorbent assay (ELISA) was used to detect the concentration of HIF-1 and VEGF in serum of rats before treatment (T0), and 3 days (T1), 5 days (T2) and 7 days (T3) after treatment, and the cardiac function was measured at the same time. The concentrations of HIF-1 and VEGF in serum of the study group and the routine therapy group after treatment were significantly higher than those before treatment. The concentrations of HIF-1 and VEGF in serum of model group at T0 were significantly lower than those at T3 (P<0.05). After treatment, the concentrations of HIF-1 and VEGF in serum of the study group were significantly higher than those of the routine therapy, the model and the control group (P<0.05). One week after administration, there were significant differences in the left ventricular function among the five groups (P<0.001). The left ventricular function in the study group was better than that in the routine therapy, model and control group. The levels of HIF-1 and VEGF in the serum of rats with myocardial infarction were negatively correlated with LVIDs and LVIDd, and positively correlated with LVEF% and LVFS%. In conclusion, atorvastatin combined with routine therapy can better reduce serum HIF-1 and VEGF levels and improve the left ventricular function in rats than routine therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Zhang

2020

Exp Ther Med

View full text Add to dashboard Cite

show abstract

“…With the development of hs-cTn analysis, diagnostic sensitivity has been further improved; however, specifi city is relatively reduced [3]. Myoglobin is an early and sensitive marker it starts to rise in the blood 2 hour after following onset of myocardial necrosis but the specifi city for the diagnosis MI to some extent [4]. Other marker CK-MB that is specifi c and starts to elevate within 3-4 hour after onset of myocardial injury but sensitivity is not higher [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have also reported that hs-CRP was a diagnostic biomarker for AMI and could potentially refl ect the extent of myocardial injury in STEMI [4,9]. So we need to a better marker for early detection that sensitivity and specifi city should be high and decline these limitations.…”

Section: Introductionmentioning

confidence: 99%

Relation of hs-CRP and Glycogen phosphorylase BB in Acute Myocardial Infarction Patients

Singh¹,

Garg²,

Rastogi³

et al. 2020

J Cardiovasc Med Cardiol

View full text Add to dashboard Cite

Background: Infl ammation has important role in the pathophysiology of atherosclerosis and acute myocardial infraction and hs-CRP is an infl ammatory marker. GPBB is a marker of myocardial necrosis or myocardial ischemia i.e. the initial phase of AMI. The aim of this study was to know the levels of GPB and the relation between hs-CRP and GPBB in AMI patients. Materials & methods: This study was conducted in the Cardiology of J.A. Hospital and Department of biochemistry, G.R. Medical College, Gwalior. Patients were admitted with severe chest pain out of which 100 were included in this study. 50 normal healthy individuals were also selected. Blood samples were collected at the admission time for the analysis of hs-CRP and GPBB. All patients underwent thorough clinical examination and investigations. Estimation of GPBB and hs-CRP were done by ELISA method and other routine parameters done by enzymatic method. Results: The mean level of GPBB in patients was 46.92ng/mL while in controls it was 13.88ng/mL. The mean level of hs-CRP in patients was 4.38mg/L while in controls it was 1.34mg/L. There was highly signifi cant difference of GPBB and hs-CRP in control group and AMI group. The fi nding of results showed that hs-CRP and GPBB was positively correlated. The levels of FBG, Triglyceride, Cholesterol, LDL, and VLDL were signifi cantly increased and HDL was decreased in AMI group when compare controls. Conclusion: Our results demonstrate that there was positive correlation of hs-CRP and GPBB in AMI patients. So along with GPBB, hs-CRP is also additional marker of myocardial ischemia and AMI.

show abstract

“…With the development of high-sensitivity cTn (hs-cTn) analysis, diagnostic sensitivity has been further improved, however, specificity is relatively reduced since serum cTn levels were also increased in renal failure or pulmonary embolism patients without MI 6, 7. Other myocardial necrosis biomarkers, such as creatine kinase MB (CK-MB) and myoglobin (MYO), were similarly lacked cardiac specificity for diagnosing myocardial infarction to some extent 8, 9. These limitations and urgent clinical requirements have promoted identifications of novel biomarkers for MI, including neuroendocrine, inflammatory, genetic and molecular biomarkers.…”

Section: Introductionmentioning

confidence: 99%

Elevated plasma S100A1 level is a risk factor for ST-segment elevation myocardial infarction and associated with post-infarction cardiac function

Fan¹,

Liu²,

Guo³

et al. 2019

Int. J. Med. Sci.

View full text Add to dashboard Cite

Aim: To investigate the association between plasma S100A1 level and ST-segment elevation myocardial infarction (STEMI) and potential significance of S100A1 in post-infarction cardiac function. Methods: We examined the plasma S100A1 level in 207 STEMI patients (STEMI group) and 217 clinically healthy subjects for routine physical examination without a history of coronary artery disease (Control group). Baseline characteristics and concentrations of relevant biomarkers were compared. The relationship between S100A1 and other plasma biomarkers was detected using correlation analysis. The predictive role of S100A1 on occurrence of STEMI was then assessed using multivariate ordinal regression model analysis after adjusting for other covariates. Results: The plasma S100A1 level was found to be significantly higher (P<0.001) in STEMI group (3197.7±1576.0 pg/mL) than in Control (1423.5±1315.5 pg/mL) group. Furthermore, the correlation analysis demonstrated plasma S100A1 level was significantly associated correlated with hypersensitive cardiac troponin T (hs-cTnT) (r = 0.32; P < 0.001), creatine kinase MB (CK-MB) (r = 0.42, P < 0.001), left ventricular eject fraction (LVEF) (r =-0.12, P = 0.01), N-terminal prohormone of brain natriuretic peptide (NT-proBNP) (r = 0.61; P < 0.001) and hypersensitive C reactive protein (hs-CRP) (r = 0.38; P < 0.001). Moreover, the enrolled subjects who with a S100A1 concentration ≤ 1965.9 pg/mL presented significantly better cardiac function than the rest population. Multivariate Logistic regression analysis revealed that S100A1 was an independent predictor for STEMI patients (OR: 0.671, 95% CI 0.500-0.891, P<0.001). In addition, higher S100A1 concentration (> 1965.9 pg/mL) significantly increased the risk of STEMI as compared with the lower level (OR: 6.925; 95% CI: 4.15-11.375; P<0.001). Conclusion: These results indicated that the elevated plasma S100A1 level is an important predictor of STEMI in combination with several biomarkers and also potentially reflects the cardiac function following the acute coronary ischemia.

show abstract

Diagnostic and prognostic value of biomarkers in acute myocardial infarction

Cited by 65 publications

References 93 publications

Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Atorvastatin combined with routine therapy on HIF-1, VEGF concentration and cardiac function in rats with acute myocardial infarction

Relation of hs-CRP and Glycogen phosphorylase BB in Acute Myocardial Infarction Patients

Elevated plasma S100A1 level is a risk factor for ST-segment elevation myocardial infarction and associated with post-infarction cardiac function

Contact Info

Product

Resources

About